Human myoblast genome therapy

查看全文 作　　者：Peter K [1]Law;Danlin M [1]Law;Eugene KW [2]Sim;Khawja H [3]Haider;Margarita N [4]Vakhromeeva;Ilia I [4]Berishvili;Leo A [4]Bockeria;Choong-Chin [5]Liew

机构地区：[1]Cell Transplants Asia Ltd., Canada;[2]National University Medical Institutes, National University of Singapore, Singapore;[3]Department of Pathology and Laboratory Medicine, University of Cincinnati, Ohio, USA;[4]Bakoulev Scientific Center for Cardiovascular Surgery, Russian Academy of Medical Sciences, Russia;[5]Bingham and Women's Hospital, The Cardiovascular Genome Unit, Harvard Medical School, USA

出　　处：《Journal of Geriatric Cardiology》索引2006年第3卷第3期,共17页

摘　　要：Human Myoblast Genome Therapy (HMGT) is a platform technology of cell transplantation, nuclear transfer, and tissue engineering. Unlike stem cells, myoblasts are differentiated, immature cells destined to become muscles. Myoblasts cultured from satellite cells of adult muscle biopsies survive, develop, and function to revitalize degenerative muscles upon transplantation. Injection injury activates regeneration of host myofibers that fuse with the engrafted myoblasts, sharing their nuclei in a common gene pool of the syncytium. Thus, through nuclear transfer and complementation, the normal human genome can be transferred into muscles of patients with genetic disorders to achieve phenotype repair or disease prevention. Myoblasts are safe and efficient gene transfer vehicles endogenous to muscles that constitute 50% of body weight. Results of over 280 HMGT procedures on Duchenne Muscular Dystrophy (DMD) subjects in the past 15 years demonstrated absolute safety. Myoblast-injected DMD muscles showed improved histology. Strength increase at 18 months post-operatively averaged 123%. In another application of HMGT on ischemic cardiomyopathy, the first human myoblast transfer into porcine myocardium revealed that it was safe and effective. Clinical trials on approximately 220 severe cardiomyopathy patients in 15 countries showed a <10% mortality. Most subjects received autologous cells implanted on the epicardial surface during coronory artery bypass graft, or injected on the endomyocardial surface percutaneously through guiding catheters. Significant increases in left ventricular ejection fraction, wall thickness, and wall motion have been reported, with reduction in perfusion defective areas, angina, and shortness of breath. As a new modality of treatment for disease in the skeletal muscle or myocardium, HMGT emerged as safe and effective. Large randomized multi-center trials are under way to confirm these preliminary results. The future of HMGT is bright and exciting. 关键词：heart REGENERATION HUMAN GENOME THERAPY MYOBLASTS

相关文献

参考文献（122）
引证文献（2）
耦合文献（2）

参考文献(122)

引证文献(2)

耦合文献(2)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Human myoblast genome therapy

参考文献(122)

引证文献(2)

耦合文献(2)

用户提示